Energy based pharmacophore mapping of HDAC inhibitors against class i HDAC enzymes

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1834, Issue 1, 2013, Pages 317-328

  Kalyaanamoorthy, Subha ^a   Chen, Yi Ping Phoebe ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

e Pharmacophore; HDAC; HDAC inhibitors; structure based descriptors

Indexed keywords

4 PHENYLBUTYRIC ACID; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; APICIDIN; BELINOSTAT; BUTYRIC ACID; DACINOSTAT; DEPSIPEPTIDE; ENTINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; OXAMFLATIN; PANOBINOSTAT; PYROXAMIDE; SK 7041; TACEDINALINE; TRAPOXIN B; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; CRYSTAL STRUCTURE; DRUG STRUCTURE; ENERGY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME STRUCTURE; GENE EXPRESSION REGULATION; MOLECULAR DOCKING; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL;

BINDING SITES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; THERMODYNAMICS;

EID: 84871721213     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2012.08.009     Document Type: Article

References (86)

1. M. Grunstein Histone acetylation in chromatin structure and transcription Nature 389 1997 349 352
2. C.M. Grozinger, and S.L. Schreiber Deacetylase Enzymes: Biological Functions and the Use of Small-Molecule Inhibitors Chem. Biol. 9 2002 3 16
3. D. Mottet, and V. Castronovo Histone deacetylases: target enzymes for cancer therapy Clin. Exp. Metastasis 25 2008 183 189
4. I.A. Kim, J.H. Shin, I.H. Kim, J.H. Kim, J.S. Kim, H.G. Wu, E.K. Chie, S.W. Ha, C.I. Park, and G.D. Kao Histone Deacetylase Inhibitor-Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53 Clin. Cancer Res. 12 2006 940 949
5. R. Wu, S. Wang, N. Zhou, Z. Cao, and Y. Zhang A Proton-Shuttle Reaction Mechanism for Histone Deacetylase 8 and the Catalytic Role of Metal Ions J. Am. Chem. Soc. 132 2010 9471 9479
6. A.J.M. de Ruijter, A.H. van Gennip, H.N. Caron, S. Kemp, and A.B.P. van Kuilenburg Histone deacetylases (HDACs): characterization of the classical HDAC family Biochem. J. 370 2003 737 749
7. M. Dokmanovic, and P.A. Marks Prospects: Histone deacetylase inhibitors J. Cell. Biochem. 96 2005 293 304
8. S. Kyrylenko, O. Kyrylenko, T. Suuronen, and A. Salminen Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases Cell. Mol. Life Sci. 60 2003 1990 1997
9. H. Park, and S. Lee Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors J. Comput. Aided Mol. Des. 18 2004 375 388
10. B.H. Huang, M. Laban, C.H.W. Leung, L. Lee, C.K. Lee, M. Salto-Tellez, G.C. Raju, and S.C. Hooi Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1//WAF1 expression, independent of histone deacetylase 1 Cell Death Differ. 12 2005 395 404
11. P. Zhu, E. Martin, J. Mengwasser, P. Schlag, K.-P. Janssen, and M. Göttlicher Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis Cancer Cell 5 2004 455 463
12. M. Nakagawa, Y. Oda, T. Eguchi, S.-I. Aishima, T. Yao, F. Hosoi, Y. Basaki, M. Ono, M. Kuwano, M. Tanaka, and M. Tsuneyoshi Expression profile of class I histone deacetylases in human cancer tissues Oncol. Rep. 18 2007 769 774
13. T. Liu, S. Kuljaca, A. Tee, and G.M. Marshall Histone deacetylase inhibitors: Multifunctional anticancer agents Cancer Treat. Rev. 32 2006 157 165
14. R. Merzvinskyte, G. Treigyte, J. Savickiene, K.-E. Magnusson, and R. Navakauskiene Effects of Histone Deacetylase Inhibitors, Sodium Phenyl Butyrate and Vitamin B3, in Combination with Retinoic Acid on Granulocytic Differentiation of Human Promyelocytic Leukemia HL-60 Cells Ann. N. Y. Acad. Sci. 1091 2006 356 367
15. V. Andrianov, V. Gailite, D. Lola, E. Loza, V. Semenikhina, I. Kalvinsh, P. Finn, K.D. Petersen, J.W.A. Ritchie, N. Khan, A. Tumber, L.S. Collins, S.M. Vadlamudi, F. Björkling, and M. Sehested Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR Eur. J. Med. Chem. 44 2009 1067 1085
16. K.V. Balakin, Y.A. Ivanenkov, A.S. Kiselyov, and S.E. Tkachenko Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective Anticancer Agents Med. Chem. 7 5 2007 576 592
17. M.S. Finnin, J.R. Donigian, A. Cohen, V.M. Richon, R.A. Rifkind, P.A. Marks, R. Breslow, and N.P. Pavletich Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 401 1999 188 193
18. Y.-d. Chen, Y.-J. Jiang, J.-W. Zhou, Q.-S. Yu, and Q.-D. You Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling J. Mol. Graph. Model. 26 2008 1160 1168
19. M. Jung, G. Brosch, D. Kolle, H. Scherf, C. Gerhauser, and P. Loidl Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation J. Med. Chem. 42 1999 4669 4679
20. S.M. Sternson, J.C. Wong, C.M. Grozinger, and S.L. Schreiber Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and Trapoxin Org. Lett. 3 2001 4239 4242
21. A.V. Bieliauskas, and M.K.H. Pflum Isoform-selective histone deacetylase inhibitors Chem. Soc. Rev. 37 2008 1402 1413
22. U. Tambunan, N. Bramantya, and A. Parikesit In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC) BMC Bioinformatics 12 2011 S23
23. R. Wu, Z. Lu, Z. Cao, and Y. Zhang Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel J. Am. Chem. Soc. 133 2011 6110 6113
24. D. Levy, and O. Gozani Decoding Chromatin Goes High Tech Cell 142 2010 844 846
25. G. Ortore, F.D. Colo, and A. Martinelli Docking of Hydroxamic Acids into HDAC1 and HDAC8: A Rationalization of Activity Trends and Selectivities J. Chem. Inf. Model. 49 2009 2774 2785
26. T.C. Karagiannis, and A. El-Osta Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 21 2006 61 65
27. W. Tang, T. Luo, E.F. Greenberg, J.E. Bradner, and S.L. Schreiber Discovery of histone deacetylase 8 selective inhibitors Bioorg. Med. Chem. Lett. 21 2011 2601 2605
28. P. Bertrand Inside HDAC with HDAC inhibitors Eur. J. Med. Chem. 45 2010 2095 2116
29. D.-F. Wang, O. Wiest, P. Helquist, H.-Y. Lan-Hargest, and N.L. Wiech On the Function of the 14Å Long Internal Cavity of Histone Deacetylase-Like Protein: Implications for the Design of Histone Deacetylase Inhibitors J. Med. Chem. 47 2004 3409 3417
30. S. Kalyaanamoorthy, and Y.-P.P. Chen Exploring Inhibitor Release Pathways in Histone Deacetylases Using Random Acceleration Molecular Dynamics Simulations J. Chem. Inf. Model. 52 2012 589 603
31. A. Vannini, C. Volpari, G. Filocamo, E.C. Casavola, M. Brunetti, D. Renzoni, P. Chakravarty, C. Paolini, R. De Francesco, P. Gallinari, C. Steinkühler, and S. Di Marco Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor Proc. Natl. Acad. Sci. U. S. A. 101 2004 15064 15069
32. G. Estiu, N. West, R. Mazitschek, E. Greenberg, J.E. Bradner, and O. Wiest On the inhibition of histone deacetylase 8 Bioorg. Med. Chem. 18 2010 4103 4110
33. L. Whitehead, M.R. Dobler, B. Radetich, Y. Zhu, P.W. Atadja, T. Claiborne, J.E. Grob, A. McRiner, M.R. Pancost, A. Patnaik, W. Shao, M. Shultz, R. Tichkule, R.A. Tommasi, B. Vash, P. Wang, and T. Stams Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors Bioorg. Med. Chem. 19 2011 4626 4634
34. Y. Itoh, Y.T. Suzuki, and T.N. Miyata Isoform-selective histone deacetylase inhibitors Curr. Pharm. Des. 14 2008 529 544
35. K.V. Butler, and A.P. Kozikowski Chemical origins of isoform selectivity in histone deacetylase inhibitors Curr. Pharm. Des. 14 2008 505 528
36. L. Yu, F. Liu, Y. Chen, and Q. You Pharmacophore Identification of Hydroxamate HDAC 1 Inhibitors Chin. J. Chem. 27 2009 557 564
37. N. Noureen, S. Kalsoom, and H. Rashid Ligand based pharmacophore modelling of anticancer histone deacetylase inhibitors Afr. J. Biotechnol. 9 2010 3923 3931
38. K. Loving, N. Salam, and W. Sherman Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation J. Comput. Aided Mol. Des. 23 2009 541 554
39. N.K. Salam, R. Nuti, and W. Sherman Novel Method for Generating Structure-Based Pharmacophores Using Energetic Analysis J. Chem. Inf. Model. 49 2009 2356 2368
40. J. Yoo, and J. Medina-Franco Homology modeling, docking and structure-based pharmacophore of inhibitors of DNA methyltransferase J. Comput. Aided Mol. Des. 25 2011 555 567
41. J.L. Aron, M.R. Parthun, G. Marcucci, S. Kitada, A.P. Mone, M.E. Davis, T. Shen, T. Murphy, J. Wickham, C. Kanakry, D.M. Lucas, J.C. Reed, M.R. Grever, and J.C. Byrd Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8Â-mediated apoptosis and down-regulation of c-FLIP protein Blood 102 2003 652 658
42. L.M. Butler, Y. Webb, D.B. Agus, B. Higgins, T.R. Tolentino, M.C. Kutko, M.P. LaQuaglia, M. Drobnjak, C. Cordon-Cardo, H.I. Scher, R. Breslow, V.M. Richon, R.A. Rifkind, and P.A. Marks Inhibition of Transformed Cell Growth and Induction of Cellular Differentiation by Pyroxamide, an Inhibitor of Histone Deacetylase Clin. Cancer Res. 7 2001 962 970
43. M.C. Crisanti, A.S. Wallace, K. Coleman, V. Kapoor, M. Dowling, G.D. Kao, and S.A. Albelda Effects of HDAC Inhibitor LBH589 in 36 Different Lung Cancer Cell Lines J. Surg. Res. 144 2008 277
44. J.-W. Han, S.H. Ahn, S.H. Park, S.Y. Wang, G.-U. Bae, D.-W. Seo, H.-K. Kwon, S. Hong, H.Y. Lee, Y.-W. Lee, and H.-W. Lee Apicidin, a Histone Deacetylase Inhibitor, Inhibits Proliferation of Tumor Cells via Induction of p21WAF1/Cip1 and Gelsolin Cancer Res. 60 2000 6068 6074
45. M. Jung, K. Hoffmann, G. Brosch, and P. Loidl Analogues of trichostatin a and trapoxin B as histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 7 1997 1655 1658
46. W.K. Kelly, T. Yap, J. Lee, U. Lassen, E. Crowley, A. Clarke, T. Hawthorne, P. Buhl-Jensen, and J. de Bono A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors J. Clin. Oncol. 25 2007 14092 (ASCO Annual Meeting Proceedings Part 1)
47. Y.B. Kim, K.H. Lee, K. Sugita, M. Yoshida, and S. Horinouchi Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase Oncogene 18 1999 2461 2470
48. H.J. Kwon, T. Owa, C.A. Hassig, J. Shimada, and S.L. Schreiber Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase Proc. Natl. Acad. Sci. 95 1998 3356 3361
49. L. Lagneaux, N. Gillet, B. Stamatopoulos, A. Delforge, M. Dejeneffe, M. Massy, N. Meuleman, A. Kentos, P. Martiat, L. Willems, and D. Bron Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response Exp. Hematol. 35 2007 1527 1537
50. D.L. Marrocco, W.D. Tilley, T. Bianco-Miotto, A. Evdokiou, H.I. Scher, R.A. Rifkind, P.A. Marks, V.M. Richon, and L.M. Butler Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation Mol. Cancer Ther. 6 2007 51 60
51. S. Prakash, B.J. Foster, M. Meyer, A. Wozniak, L.K. Heilbrun, L. Flaherty, M. Zalupski, L. Radulovic, M. Valdivieso, and P.M. LoRusso Chronic Oral Administration of CI-994: A Phase I Study Invest. New Drugs 19 2001 1 11
52. J.K. Ryu, W.J. Lee, K.H. Lee, J.-H. Hwang, Y.-T. Kim, Y.B. Yoon, and C.Y. Kim SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines Cancer Lett. 237 2006 143 154
53. N. Takai, T. Ueda, M. Nishida, K. Nasu, K. Matsuda, M. Kusumoto, and H. Narahara CBHA Is a Family of Hybrid Polar Compounds That Inhibit Histone Deacetylase, and Induces Growth Inhibition, Cell Cycle Arrest and Apoptosis in Human Endometrial and Ovarian Cancer Cells Oncology 70 2006 97 105
54. E. Weisberg, L. Catley, J. Kujawa, P. Atadja, S. Remiszewski, P. Fuerst, C. Cavazza, K. Anderson, and J.D. Griffin Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo Leukemia 18 2004 1951 1963
55. D.M. Lucas, M.E. Davis, M.R. Parthun, A.P. Mone, S. Kitada, K.D. Cunningham, E.L. Flax, J. Wickham, J.C. Reed, J.C. Byrd, and M.R. Grever The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells Leukemia 18 2004 1207 1214
56. S.D. Gore, and M.A. Carducci Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors Expert Opin. Investig. Drugs 9 2000 2923 2934
57. P. Gallinari, S.D. Marco, P. Jones, M. Pallaoro, and C. Steinkuhler HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics Cell Res. 17 2007 195 211
58. K. Subha, and G. Ramesh Kumar Assessment for the identification of better HDAC inhibitor class through binding energy calculations and descriptor analysis Bioinformation 3 2008 218 222
59. H.-Y. Lin, C.-S. Chen, S.-P. Lin, J.-R. Weng, and C.-S. Chen Targeting histone deacetylase in cancer therapy Med. Res. Rev. 26 2006 397 413
60. P.J. Watson, L. Fairall, G.M. Santos, and J.W.R. Schwabe Structure of HDAC3 bound to co-repressor and inositol tetraphosphate Nature 481 2012 335 340
61. S. Vadivelan, B.N. Sinha, G. Rambabu, K. Boppana, and S.A.R.P. Jagarlapudi Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads J. Mol. Graph. Model. 26 2008 935 946
62. J.C. Bressi, A.J. Jennings, R. Skene, Y. Wu, R. Melkus, R.D. Jong, S. O'Connell, C.E. Grimshaw, M. Navre, and A.R. Gangloff Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides Bioorg. Med. Chem. Lett. 20 2010 3142 3145
63. S. Kalyaanamoorthy, and Y.-P.P. Chen Structure-based drug design to augment hit discovery Drug Discov. Today 16 2011 831 839
64. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne The Protein Data Bank Nucleic Acids Res. 28 2000 235 242
65. Y.-C. Lin, J.-H. Lin, C.-W. Chou, Y.-F. Chang, S.-H. Yeh, and C.-C. Chen Statins Increase p21 through Inhibition of Histone Deacetylase Activity and Release of Promoter-Associated HDAC1/2 Cancer Res. 68 2008 2375 2383
66. R.H. Stote, and M. Karplus Zinc binding in proteins and solution: A simple but accurate nonbonded representation Proteins: Struct. Funct. Bioinf. 23 1995 12 31
67. S.V.W. Weerasinghe, G. Estiu, O. Wiest, and M.K.H. Pflum Residues in the 11 Ã. Channel of Histone Deacetylase 1 Promote Catalytic Activity: Implications for Designing Isoform-Selective Histone Deacetylase Inhibitors J. Med. Chem. 51 2008 5542 5551
68. G.A. Kaminski, R.A. Friesner, J. Tirado-Rives, and W.L. Jorgensen Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides † J. Phys. Chem. B 105 2001 6474 6487
69. M.P. Jacobson, R.A. Friesner, Z. Xiang, and B. Honig On the Role of the Crystal Environment in Determining Protein Side-chain Conformations J. Mol. Biol. 320 2002 597 608
70. M.P. Jacobson, D.L. Pincus, C.S. Rapp, T.J.F. Day, B. Honig, D.E. Shaw, and R.A. Friesner A hierarchical approach to all-atom protein loop prediction Proteins: Struct. Funct. Bioinf. 55 2004 351 367
71. LigPrep v2.5 2011 Schrödinger LLC New York, NY
72. W.L. Jorgensen, and J. Tirado-Rives The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin J. Am. Chem. Soc. 110 1988 1657 1666
73. G.A. Kaminski, R.A. Friesner, J. Tirado-Rives, and W.L. Jorgensen Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides†J. Phys. Chem. B 105 2001 6474 6487
74. Glide v5.0 2011 Schrödinger, LLC New York, NY
75. R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren, P.C. Sanschagrin, and D.T. Mainz Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes J. Med. Chem. 49 2006 6177 6196
76. P.D. Lyne, M.L. Lamb, and J.C. Saeh Accurate Prediction of the Relative Potencies of Members of a Series of Kinase Inhibitors Using Molecular Docking and MM-GBSA Scoring J. Med. Chem. 49 2006 4805 4808
77. T. Hou, J. Wang, Y. Li, and W. Wang Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations J. Chem. Inf. Model. 51 2010 69 82
78. Phase v4.0 2011 Schrödinger, LLC New York, NY
79. Prime v3.0 2011 Schrödinger, LLC New York, NY
80. E. Yuriev, M. Agostino, and P.A. Ramsland Challenges and advances in computational docking: 2009 in review J. Mol. Recognit. 24 2011 149 164
81. A. Vannini, C. Volpari, P. Gallinari, P. Jones, M. Mattu, A. Carfi, R. De Francesco, C. Steinkuhler, and S. Di Marco Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex EMBO Rep. 8 2007 879 884
82. I. Schomburg, A. Chang, C. Ebeling, M. Gremse, C. Heldt, G. Huhn, and D. Schomburg BRENDA, the enzyme database: updates and major new developments Nucleic Acids Res. 32 2004 D431 D433
83. A. Mai, S. Massa, D. Rotili, I. Cerbara, S. Valente, R. Pezzi, S. Simeoni, and R. Ragno Histone deacetylation in epigenetics: An attractive target for anticancer therapy Med. Res. Rev. 25 2005 261 309
84. P.A. Marks, V.M. Richon, T. Miller, W.K. Kelly, F.V.W. George, and K. George Histone Deacetylase Inhibitors Advances in Cancer Research vol. 91 2004 Academic Press 137 168
85. K. Huber, G. Doyon, J. Plaks, E. Fyne, J.W. Mellors, and N. Sluis-Cremer Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV-1 from latently infected cells J. Biol. Chem. 286 25 2011 22211 222118
86. Y. Zhu, H.-F. Li, S. Lu, Y.-X. Zheng, Z. Wu, W.-F. Tang, X. Zhou, and T. Lu Investigation on the isoform selectivity of histone deacetylase inhibitors using chemical feature based pharmacophore and docking approaches Eur. J. Med. Chem. 45 2010 1777 1791